Teriparatide biosimilar - USV

Drug Profile

Teriparatide biosimilar - USV

Alternative Names: Recombinant parathyroid hormone biosimilar - USV

Latest Information Update: 23 May 2015

Price : $50

At a glance

  • Originator USV
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 May 2015 USV files a patent for teriparatide biosimilar before May 2015 (USV product pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top